Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

October 6, 2017: By Jon Swedien

legal issuesShire filed a lawsuit against Allergan on Oct. 2, alleging its competitor in the dry eye market has used an “anticompetitive scheme” to block or limit Xiidra’s entry into Medicare Part D prescription drug plans.

In the suit, Shire argues Allergan uses bundled discounts—which leverage Allergan’s glaucoma medications—as well as exclusive deals and other methods to keep Xiidra’s market share in Medicare Part D plans to 10 percent, compared with Restasis’ 90 percent. Conversely, Xiidra has achieved a 35 percent share in commercial drug plans since its US FDA approval in July 2016, according to Shire’s suit.

Allergan spokesman Mark Marmur told Reuters the lawsuit has no merit, and the company complies with Medicare procedures.

Shire filed the complaint in the US District Court of New Jersey.

In the complaint, Shire states one Medicare prescription drug plan told the company: “You could give [Xiidra] to us for free, and the numbers still wouldn’t work,” because of the bundled package Allergan offered.

Shire claims in the suit that patients can appeal for Xiidra when their plan only offers Restasis, but this increases their copays by two to five times.

In addition, Shire said that, when it has gotten Medicare plans to offer Xiidra, it’s often as a “non-preferred” item, which also increases copays by two to five times.

Shire argued that Allergan’s methods do not save patients any money because Restasis must often be used in conjunction with a topical prescription steroid, while Xiidra has the same list price as Restasis and does not require the use of any additional drugs.

Shire claimed that Allergan’s methods also hurt consumers because Restasis is approved to treat a limited subset of dry eye patients, while Xiidra is approved to treat all of the signs and symptoms of dry eye and can be prescribed to treat more patients.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022